Informe final de la beca BE realizada en la California San Francisco

Investigaci��n producida a partir de una estancia de dos meses en el laboratorio de la Dra. Donna M. Ferriero del departamento de neurolog��a de la University of Californai San Francisco. A partir de un modelo de lesi��n cerebral isquemica en ratas postnatales, se han estudiado los efectos de la interacci��n con integrinas en el desarrollo de la lesi��n como estrategia terap��utica.

Nota metodol��gica sobre la determinaci��n de sectores "clave" en el consumo de energ��a final: una primera aproximaci��n al caso espa��ol

En este art��culo analizamos la determinaci��n de sectores "clave" en el consumo de energ��a final. Enfocamos esta cuesti��n desde una perspectiva input-output, dise��ando una metodolog��a basada en las elasticidades de la demanda del consumo de energ��a final. A modo de ejercicio, aplicamos la metodolog��a a la econom��a espa��ola. El an��lisis permite se��alar la mayor o menor relevancia de los distintos sectores en el consumo energ��tico final, indicando qu�� sectores merecen mayor atenci��n en el caso espa��ol y apuntando las implicaciones para la pol��tica energ��tica.

Methodological note about the determination of key sectors in final energy consumption: a preliminary approach to the Spanish case

In this paper we analyze the determination of "key" sectors in the final energy consumption. We approach this issue from an input-output perspective and we design a methodology based on the elasticities of the demands of final energy consumption. As an exercise, we apply the proposed methodology to the Spanish economy. The analysis allows us to indicate the greater or lesser relevance of the different sectors in the consumption of final energy, pointing out which sectors deserve greater attention in the Spanish case and showing the implications for energy policy.

Jornada de presentaci��n y debate en torno al Libro Verde de la Accesibilidad en Espa��a : informe final

La Jornada ha pretendido avanzar hacia la definici��n de un Libro Blanco que recoja la perspectiva y opiniones de los distintos agentes implicados en la accesibilidad a los distintos entornos y servicios relacionados con la edificaci��n, el urbanismo, los transportes y la comunicaci��n e informaci��n. Para ello se ha partido de la presentaci��n y debate de los contenidos del Libro Verde y de las propuestas del equipo redactor. Este documento resume los aspectos m��s destacables de la Jornada dando prioridad a los debates y aportaciones producidas en los talleres sectoriales. En ��l no se incluyen los res��menes o el contenido de las presentaciones realizadas en las sesiones plenarias.

I Plan Nacional de Accesibilidad 2004-2012: Informe de aplicaci��n. Memoria final

Para arrancar y poner en pr��ctica el Plan se ha considerado la necesidad de desarrollar una ���hoja de ruta��� (Informe de Puesta en Marcha y Aplicaci��n) de cada una de las acciones consideradas m��s prioritarias en el primer trienio, a modo de gu��a para su implementaci��n.

Actividad econ��mica, consumo final de energ��a y requerimientos de energ��a primaria en Catalu��a, 1990-2005. An��lisis mediante el uso de los balances energ��ticos desde una perspectiva input-output

Este trabajo analiza la evoluci��n de los consumos finales de energ��a en Catalu��a durante el periodo 1990-2005. En conjunto, los consumos finales de energ��a crecen por encima del crecimiento del PIB en t��rminos reales. La disponibilidad actual de datos permite una desagregaci��n en cinco actividades: sector primario; sector industrial; sector servicios; transporte; y sector dom��stico. Los aumentos relativos m��s importantes se dan en los sectores servicios, dom��stico y transporte. Es esta ��ltima actividad (que incluye el transporte privado y comercial) la que experimenta un mayor aumento en t��rminos absolutos, hasta llegar a representar un consumo final de energ��a.

Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).

BACKGROUND: The aim of this study was to evaluate the efficacy and tolerability of fulvestrant, an estrogen receptor antagonist, in postmenopausal women with hormone-responsive tumors progressing after aromatase inhibitor (AI) treatment. PATIENTS AND METHODS: This is a phase II, open, multicenter, noncomparative study. Two patient groups were prospectively considered: group A (n=70) with AI-responsive disease and group B (n=20) with AI-resistant disease. Fulvestrant 250 mg was administered as intramuscular injection every 28 (+/-3) days. RESULTS: All patients were pretreated with AI and 84% also with tamoxifen or toremifene; 67% had bone metastases and 45% liver metastases. Fulvestrant administration was well tolerated and yielded a clinical benefit (CB; defined as objective response or stable disease [SD] for >or=24 weeks) in 28% (90% confidence interval [CI] 19% to 39%) of patients in group A and 37% (90% CI 19% to 58%) of patients in group B. Median time to progression (TTP) was 3.6 (95% CI 3.0 to 4.8) months in group A and 3.4 (95% CI 2.5 to 6.7) months in group B. CONCLUSIONS: Overall, 30% of patients who had progressed following prior AI treatment gained CB with fulvestrant, thereby delaying indication to start chemotherapy. Prior response to an AI did not appear to be predictive for benefit with fulvestrant.

Early-onset Crohn's disease is a risk factor for smaller final height.

OBJECTIVES: Growth retardation is a frequent complication of paediatric inflammatory bowel disease (IBD). Only a few studies report the final height of these patients, with controversial results. We compared adult height of patients with paediatric IBD with that of patients with adult-onset disease. METHODS: Height data of 675 women 19-44 years of age and 454 men 23-44 years of age obtained at inclusion in the Swiss IBD cohort study registry were grouped according to the age at diagnosis: (a) prepubertal (men&#8804;13, women&#8804;11 years), (b) pubertal (men 13-22, women 11-18 years) and (c) adult (men>22, women>18 years of age), and compared with each other and with healthy controls. RESULTS: Male patients with prepubertal onset of Crohn's disease (CD) had significantly lower final height (mean 172��6&#8201;cm, range 161-182) compared with men with pubertal (179��6&#8201;cm, 161-192) or adult (178��7&#8201;cm, 162-200) age at onset and the general population (178��7&#8201;cm, 142-204). Height z-scores standardized against heights of the normal population were significantly lower in all patients with a prepubertal diagnosis of CD (-0.8��0.9) compared with the other patient groups (-0.1��0.8, P<0.001). Prepubertal onset of CD emerged as a risk factor for reduced final height in patients with prepubertal CD. No difference for final height was found between patients with ulcerative or unclassified IBD diagnosed at prepubertal, pubertal or adult age. CONCLUSION: Prepubertal onset of CD is a risk for lower final height, independent of the initial disease location and the necessity for surgical interventions.

Aplicaci�� per a la creaci�� de guies d'avaluaci�� de compet��ncies als treballs de final d'estudis

Aquest projecte neix per facilitar l�����s de la ���Guia per a l���avaluaci�� de compet��ncies als treballs de final de grau i m��ster a les enginyeries��� elaborada per un grup de professors de sis universitats p��bliques catalanes, de tres titulacions d���Enginyeria (Enginyeria Inform��tica, Enginyeria de Telecomunicacions i Enginyeria Qu��mica). Per facilitar l'��s de la Guia s���ha implementat aquesta aplicaci�� web que permet definir de forma senzilla i efectiva els procediments per a realitzar l'avaluaci�� de compet��ncies en els Treballs de Fi de Grau (TFG) i de Fi de M��ster (TFM).

I si deixem de parlar de preservaci�� digital? Variacions sobre un tema de David Rosenthal, amb un poutpourri final amb la CDLib Orchestra

La preservaci�� digital de la que parla la nostra literatura professional est�� plena de mites que pensem que s'han d'anar tombant un darrera l'altre, en aquesta presentaci�� us els mencionarem.

Inequality across countries in energy intensities: an analysis of the role of energy transformation and final energy consumption

This paper analyzes the role of the energy transformation index and of final energy consumption per GDP unit in the disparities in energy intensity across countries. In that vein, we use a Theil decomposition approach to analyze global primary energy intensity inequality as well as inequality across different regions of the world and inequality within these regions. The paper first demonstrates the pre-eminence of divergence in final energy consumption per GDP unit in explaining global primary energy intensity inequality and its evolution during the 1971-2006 period. Secondly, it shows the lower (albeit non negligible) impact of the transformation index in global primary energy inequality. Thirdly, the relevance of regions as unit of analysis in studying crosscountry energy intensity inequality and their explanatory factors is highlighted. And finally, how regions around the world differ as to the relevance of the energy transformation index in explaining primary energy intensity inequality.

Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial.

BACKGROUND: Allogeneic stem cell transplantation is usually considered the only curative treatment option for patients with advanced or transformed myelodysplastic syndromes in complete remission, but post-remission chemotherapy and autologous stem cell transplantation are potential alternatives, especially in patients over 45 years old. DESIGN AND METHODS: We evaluated, after intensive anti-leukemic remission-induction chemotherapy, the impact of the availability of an HLA-identical sibling donor on an intention-to treat basis. Additionally, all patients without a sibling donor in complete remission after the first consolidation course were randomized to either autologous peripheral blood stem cell transplantation or a second consolidation course consisting of high-dose cytarabine. RESULTS: The 4-year survival of the 341 evaluable patients was 28%. After achieving complete remission, the 4-year survival rates of patients under 55 years old with or without a donor were 54% and 41%, respectively, with an adjusted hazard ratio of 0.81 (95% confidence interval [95% CI], 0.49-1.35) for survival and of 0.67 (95% CI, 0.42-1.06) for disease-free survival. In patients with intermediate/high risk cytogenetic abnormalities the hazard ratio in multivariate analysis was 0.58 (99% CI, 0.22-1.50) (P=0.14) for survival and 0.46 (99% CI, 0.22-1.50) for disease-free survival (P=0.03). In contrast, in patients with low risk cytogenetic characteristics the hazard ratio for survival was 1.17 (99% CI, 0.40-3.42) and that for disease-free survival was 1.02 (99% CI, 0.40-2.56). The 4-year survival of the 65 patients randomized to autologous peripheral blood stem cell transplantation or a second consolidation course of high-dose cytarabine was 37% and 27%, respectively. The hazard ratio in multivariate analysis was 1.22 (95% CI, 0.65-2.27) for survival and 1.02 (95% CI, 0.56-1.85) for disease-free survival. CONCLUSIONS: Patients with a donor and candidates for allogeneic stem cell transplantation in first complete remission may have a better disease-free survival than those without a donor in case of myelodysplastic syndromes with intermediate/high-risk cytogenetics. Autologous peripheral blood stem cell transplantation does not provide longer survival than intensive chemotherapy.